Stock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership

Stock Track

Apr 15

3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.

The rally appears driven by positive developments for the company's pipeline. Its independently developed drug candidate SSS67 has officially received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), following a prior IND clearance from the U.S. Food and Drug Administration (FDA). This represents a key dual-market regulatory milestone for the asset.

Further bolstering investor sentiment is the company's landmark partnership with Pfizer, a deal valued at up to over USD 6 billion, which includes a record-setting upfront payment of USD 1.4 billion for a domestically developed innovative drug. Analysts note that southbound capital flows, which were a key driver during the stock's previous major rally, remain a factor to watch.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1142533714"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142533714\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142533714?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 11:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142533714","market":"hk","top_or_hot":-1,"title":"Stock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership","media":"Stock Track","content":"<p>3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.</p><p>The rally appears driven by positive developments for the company's pipeline. Its independently developed drug candidate SSS67 has officially received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), following a prior IND clearance from the U.S. Food and Drug Administration (FDA). This represents a key dual-market regulatory milestone for the asset.</p><p>Further bolstering investor sentiment is the company's landmark partnership with Pfizer, a deal valued at up to over USD 6 billion, which includes a record-setting upfront payment of USD 1.4 billion for a domestically developed innovative drug. Analysts note that southbound capital flows, which were a key driver during the stock's previous major rally, remain a factor to watch.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-15 11:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.</p><p>The rally appears driven by positive developments for the company's pipeline. Its independently developed drug candidate SSS67 has officially received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), following a prior IND clearance from the U.S. Food and Drug Administration (FDA). This represents a key dual-market regulatory milestone for the asset.</p><p>Further bolstering investor sentiment is the company's landmark partnership with Pfizer, a deal valued at up to over USD 6 billion, which includes a record-setting upfront payment of USD 1.4 billion for a domestically developed innovative drug. Analysts note that southbound capital flows, which were a key driver during the stock's previous major rally, remain a factor to watch.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1142533714","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142533714","pubTimestamp":1776225076,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.The rally appears driven by positive developments for the company's pipeline. Its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"个股追踪|SSS67与辉瑞合作获双IND批准三生制药盘中大涨5.12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.The rally appears driven by positive developments for the company's pipeline. Its independently developed drug candidate SSS67 has officially received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), following a prior IND clearance from the U.S. Food and Drug Administration (FDA). This represents a key dual-market regulatory milestone for the asset.Further bolstering investor sentiment is the company's landmark partnership with Pfizer, a deal valued at up to over USD 6 billion, which includes a record-setting upfront payment of USD 1.4 billion for a domestically developed innovative drug. Analysts note that southbound capital flows, which were a key driver during the stock's previous major rally, remain a factor to watch.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}